Tylenol's sales amounted to ₩83.1 billion last year

Demand for COVID-19 vaccinations surged and sales rose 118% from the previous year to become the No. 1 OTC

The heyday brought about by Pandemic

OTC Tylenol recorded the highest sales ever.

 

Sales more than doubled last year from the previous year due to a surge in demand for COVID-19 vaccinations.

 

However, growth slowed in the second half of last year as demand for Tylenol was resolved.

 

According to IQVIA, a pharmaceutical research institute, sales of the Tylenol series last year amounted to 83.1 billion won, up 118.4% from 38.1 billion won a year earlier.

 

It is sales of four types: Tylenol, Tylenol 8-hour ER, Tylenol Cold, and Women's Tylenol.

 

Sales of the Tylenol series did not change much from 20 billion won to 30 billion won every year, but soared suddenly last year.

 

Sales of Tylenol and Tylenol 8-hour ER, which are used as antipyretic analgesics, surged.

 

Sales of Tylenol and Tylenol 8-hour ER totaled 80.2 billion won last year, up 133.4% from the previous year.

 

Tylenol's sales surged 159.4% from 24.3 billion won in 2020 to 62.9 billion won last year, while Tylenol's 8-hour ER sales rose 71.1% from the previous year to 17.3 billion won last year.

 

It is analyzed that sales have increased significantly as COVID-19 vaccinations started purchasing Tylenol in preparation for fever and muscle pain.

 

As COVID-19 vaccinations began in earnest in Korea from the beginning of last year, demand for Tylenol surged.

 

Tylenol ranked first in sales among all OTCs last year.

 

It was also pointed out that the government contributed to the surge in Tylenol's sales.

 

The quarantine authorities informed those subject to vaccination in March last year, "If side effects such as fever occur, it is better to take Tylenol." Since then, the demand for purchasing Tylenol has soared, leading to a shortage.

 

According to quarterly sales of acetaminophen single-drug Tylenol, it surged in the first half of last year and slowed down somewhat in the second half.

 

Sales of Tylenol and Tylenol 8-hour ER more than tripled from the previous quarter from 10.7 billion won in the first quarter of last year to 32.9 billion won in the second quarter.

 

In the case of Tylenol, sales more than tripled from 8.1 billion won in the first quarter of last year to 25.5 billion won in the second quarter, while Tylenol 8-hour Al also expanded from 2.6 billion won to 7.5 billion won during the same period.

 

Sales of Tylenol and Tylenol 8-hour ER jumped sharply from the previous year to 20.4 billion won and 16.2 billion won in the third and fourth quarters of last year, respectively, but decreased from the second quarter.

 

Sales in the fourth quarter of last year fell by half compared to the second quarter.

 

It is analyzed that the unstable supply and demand of Tylenol has been resolved and sales of Tylenol have been on the decline through the purchase of generics.

 

In May last year, the MFDS disclosed information that more than 60 acetaminophen single agents were on sale in addition to Tylenol, inducing the purchase of other products with the same ingredients.

 

In June last year, the MFDS decided to cooperate with KPA, KPBMA, and KPDA in the smooth supply of Acetaminophen.

 

KPDA also urgently implemented a plan to supply Acetaminophen drugs, which are supplied first from producers, to pharmacies nationwide.